Efficacy of sorafenib in treating metastatic non-clear cell renal cell carcinoma
10.3760/cma.j.issn.1000-6702.2010.01.005
- VernacularTitle:索拉非尼治疗转移性非透明细胞肾癌的疗效观察
- Author:
Hailiang ZHANG
;
Dingwei YE
;
Xudong YAO
;
Shilin ZHANG
;
Bo DAI
;
Yijun SHEN
;
Yao ZHU
;
Yiping ZHU
;
Guohai SHI
;
Chunguang MA
;
Wenjun XIAO
;
Xiaojian QIN
;
Guowen LIN
- Publication Type:Journal Article
- Keywords:
Carcinoma,renal cell;
Non-clear cell;
Neoplasm metastasis;
Sorafenib
- From:
Chinese Journal of Urology
2010;31(1):18-20
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of sorafenib in treating metastatic non-clear cell renal cell carcinoma(RCC).Methods Twenty-one patients with metastatic non-clear cell subtype renal cell carcinoma were treated with sorafenib.Thirteen cases were male,8 were female,with a median age of 45 years(25-76 years).Metastasis occurred in 12 cases after radical nephrectomy,and the other 9 cases received cytoreductive surgery.Pathological diagnosis showed 15 papillary RCCs,1 chromophobe RCC,and 5 unclassified RCCs.The metastatic lesions were located at lung,lymph node,adrenal gland,bone,liver,and thyroid gland.The patients were given the treatment of sorafenib 400 mg bid,or sorafenib 400 mg bid in combination with interferon-α 3 MIU,IH.5 days per week,and the median time of treatment was 8 months (2-21 months).Results Three cases (14.3%)with 1 papillary RCC,1 chromophobe RCC,and 1 unclassified RCC reached partial remission(PR) and 13 cases (61.9%) maintained stable disease (SD) for more than 12 weeks.And the rest 5 cases(23.8%) progressed(PD).To Jul 2009,13 cases progressed and the median progression free survival was 7 months(0-21 months).Conclusions Sorafenib has definitive efficacy in metastatic papillary RCC,chromophobe RCC,and unclassified RCC.Metastatic lesions in lungs and Lymph nodes might be more sensitive to sorafenib.
